Cost-effectiveness of Adjuvant Pembrolizumab after Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection from a Markov Model

Vidit Sharma, Kevin M. Wymer, Daniel D. Joyce, James Moriarty, Abhinav Khanna, Bijan J. Borah, R. Houston Thompson, Brian A. Costello, Bradley C. Leibovich, Stephen A. Boorjian

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Cost-effectiveness of Adjuvant Pembrolizumab after Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection from a Markov Model'. Together they form a unique fingerprint.

Medicine & Life Sciences